| Literature DB >> 30782941 |
Lauren A Maggio1, Chelsea L Ratcliff2, Melinda Krakow3, Laura L Moorhead4, Asura Enkhbayar5, Juan Pablo Alperin5.
Abstract
OBJECTIVE: To characterise how online media coverage of journal articles on cancer funded by the US government varies by cancer type and stage of the cancer control continuum and to compare the disease prevalence rates with the amount of funded research published for each cancer type and with the amount of media attention each receives.Entities:
Keywords: cancer; grant funding; information technology; media; medical journalism
Year: 2019 PMID: 30782941 PMCID: PMC6368156 DOI: 10.1136/bmjopen-2018-025783
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
PubMed search strategy for US government-funded research on cancer
| Keywords | neoplasm[mesh] OR "neoplasm metastasis"[mesh] OR cancer*[tiab] OR malign*[tiab] OR neoplas*[tiab] OR oncolo*[tiab] OR metasta*[tiab] OR tumor*[tiab] OR tumour*[tiab] |
| Funding | "research support, american recovery and reinvestment act"[Publication Type] OR "research support, n i h, extramural"[Publication Type] OR "research support, n i h, intramural"[Publication Type] OR "research support, non u s gov’t"[Publication Type] OR "research support, u s gov’t, non p h s"[Publication Type] OR "research support, u s gov’t, p h s"[Publication Type] OR "research support, u s government"[Publication Type] |
| Publication date | "2016/01/01"[Date - Publication]: "2016/12/31"[Date - Publication] |
Number of articles reporting each source of funding support
| Funding source* | Number of articles |
| NIH Extramural | 10 377 |
| NIH Intramural | 594 |
| American Recovery & Reinvestment Act | 10 |
| US government Non-Public Health Services | 1922 |
| US government Public Health Services | 295 |
| Non-US government | 6746 |
*Funding sources defined: https://www.nlm.nih.gov/pubs/techbull/mj05/mj05_support_heading.html
Common cancer types covered by journal articles resulting from US government funds in relation to the number of estimated new cases in 2017 and estimated deaths21
| Cancer type | No. of scientific articles published in 2016 (n=4984*) | No. of estimated new cases (rank) | No. of estimated deaths (rank) |
| Breast | 1284 | 2 55 190† (1) | 41 070‡ (4) |
| Lung | 630 | 2 22 500 (2) | 1 55 870 (1) |
| Prostate | 586 | 1 61 360 (3) | 26 730 (6) |
| Colon and rectal | 535 | 1 35 430 (4) | 50 260 (2) |
| Leukaemia | 544 | 62 130 (9) | 24 500 (7) |
| Pancreatic | 309 | 53 670 (12) | 43 090 (3) |
| Liver | 302 | 40 710 (13) | 28 920 (5) |
| Melanoma | 302 | 87 110 (5) | 9730 (12) |
| Non-Hodgkin’s lymphoma | 170 | 72 240 (7) | 20 140 (8) |
| Kidney | 106 | 63 990 (8) | 14 400 (10) |
| Endometrial | 77 | 61 380 (10) | 10 920 (11) |
| Thyroid | 71 | 56 870 (11) | 2010 (13) |
| Urinary/bladder | 68 | 79 030 (6) | 16 870 (9) |
*Articles may be counted multiple times if they include two or more cancers.
†Breast cancer total new cases 2 55 190 (25 2710 females; 2470 males).
‡Breast cancer total estimated deaths 41 070 (40 610 females; 460 males).
Figure 1Common cancer types covered by journal articles resulting from US government funds in relation to the number of estimated new cases in 2017 and estimated deaths.21 *NH, non-Hodgkin.
Top 10 journals featuring the most US government-funded cancer research articles, with and without media coverage
| Journal | Total funded articles in 2016 (% of total articles) | Funded articles with media coverage (% of articles in journal) | Funded articles without media coverage (% of articles in journal) | |
| 1 |
| 292 (2.6) | 88 (30.1) | 204 (69.9) |
| 2 |
| 190 (1.7) | 20 (10.5) | 170 (89.5) |
| 3 |
| 179 (1.6) | 84 (46.9) | 95 (53.1) |
| 4 |
| 151 (1.3) | 2 (1.3) | 149 (98.7) |
| 5 |
| 149 (1.3) | 40 (26.8) | 109 (73.2) |
| 6 |
| 147 (1.3) | 10 (6.8) | 137 (93.2) |
| 7 |
| 145 (1.3) | 25 (17.2) | 120 (82.8) |
| 8 |
| 125 (1.1) | 27 (21.6) | 98 (78.4) |
| 9 |
| 118 (1.0) | 10 (8.5) | 108 (91.5) |
| 10 |
| 112 (1.0) | 13 (11.6) | 99 (88.4) |
Scientific journal articles that identify a stage of cancer continuum
| Cancer type | Prevention and control articles (%) | Prevention and control articles with 1+media mentions (%) | Diagnosis articles | Diagnosis articles with 1+media mentions (%) | Therapy articles | Therapy articles with 1+media mentions (%) |
| Breast | 55 (4.3) | 21 (38.2) | 147 (11.4) | 30 (20.4) | 111 (8.6) | 24 (21.6) |
| Lung | 25 (4.0) | 4 (16.0) | 68 (10.8) | 10 (14.7) | 70 (11.1) | 12 (17.1) |
| Colon and rectal | 53 (9.9) | 19 (35.8) | 123 (23.0) | 27 (22.0) | 45 (8.4) | 7 (15.6) |
| Leukaemia | 18 (3.3) | 3 (16.7%) | 52 (9.6) | 11 (21.2) | 87 (16.0) | 16 (18.4) |
| Liver | 15 (5.0) | 2 (13.3) | 28 (9.3) | 1 (3.6) | 35 (11.6) | 6 (17.1) |
| Prostate | 25 (4.3) | 8 (32.0) | 68 (11.6) | 18 (26.5) | 53 (9.0) | 9 (17.0) |
| Melanoma | 11 (3.6) | 5 (45.5) | 24 (7.9) | 6 (25.0) | 44 (14.6) | 11 (25.0) |
| Pancreatic | 11 (3.6) | 2 (18.2) | 28 (9.1) | 3 (10.7) | 36 (11.7) | 4 (11.1) |
| Non-Hodgkin’s lymphoma | 2 (1.2) | 0 (0.0) | 21 (12.4) | 3 (14.3) | 31 (18.2) | 8 (25.8) |
| Kidney | 1 (0.9) | 0 (0.0) | 12 (11.3) | 0 (0.0) | 9 (8.5) | 2 (22.2) |
| Thyroid | 1 (1.4) | 0 (0.0) | 7 (9.9) | 0 (0.0) | 6 (8.5) | 3 (50.0) |
| Urinary/bladder | 3 (4.4) | 1 (33.3) | 12 (17.6) | 1 (8.3) | 13 (19.1) | 0 (0.0) |
| Endometrial | 3 (3.9) | 1 (33.3) | 5 (6.5) | 0 (0.0) | 8 (10.4) | (0.0) |
|
|
|
|
| |||
|
|
|
|
|
*Articles may address more than one stage in the cancer continuum. Therefore, these two totals do not reflect unique articles.
Figure 2Articles indexed as addressing the prevention and control, diagnosis or therapy stages of the cancer continuum. Articles may address more than one stage in the cancer continuum. Therefore, these two totals do not reflect unique articles. *NH, non-Hodgkin.
Top 10 articles by media mentions
| Rank | Journal | Article title | No of media mentions |
| 1 |
| Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women | 462 |
| 2 |
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | 355 |
| 3 |
| The risk of cancer in patients with psoriasis: A population-based cohort study in the Health Improvement Network | 346 |
| 4 |
| Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement | 317 |
| 5 |
| Mutational signatures associated with tobacco smoking in human cancer | 244 |
| 6 |
| Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan | 221 |
| 7 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial | 200 |
| 8 |
| CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 | 183 |
| 9 |
| The phenotypic legacy of admixture between modern humans and Neanderthals | 178 |
| 10 |
| Association of religious service attendance with mortality among women | 176 |
*Oncogene is a Nature journal.
Number of scientific articles about common cancer types in relation to media mentions
| Cancer type* | Total scientific articles | Articles (%) with at least one media mention | Total media mentions across articles | Average number of media mentions per article of those with mentions (range) |
| Breast | 1284 | 251 (19.5) | 2152 | 8.57 (1–118) |
| Lung | 630 | 115 (18.3) | 1043 | 9.07 (1–100) |
| Colon | 535 | 116 (21.7) | 1585 | 13.66 (1–317) |
| Leukaemia | 544 | 114 (21.0) | 830 | 7.28 (1–57) |
| Liver | 302 | 51 (16.9) | 518 | 10.16 (1–117) |
| Prostate | 586 | 116 (19.8) | 984 | 8.48 (1–160) |
| Melanoma | 302 | 75 (24.8) | 938 | 12.51 (1–139) |
| Pancreatic | 309 | 61 (19.7) | 491 | 8.05 (1–83) |
| Non-Hodgkin’s lymphoma | 170 | 33 (19.4) | 181 | 5.48 (1–61) |
| Kidney | 106 | 22 (20.8) | 494 | 22.45 (1–355) |
| Thyroid | 71 | 5 (7.0) | 51 | 10.20 (1–31) |
| Urinary/bladder | 68 | 11 (16.2) | 27 | 2.45 (1–9) |
| Endometrial | 77 | 12 (16.8) | 109 | 9.08 (1–45) |
*Articles can be included in more than one cancer type.
Figure 3Articles with at least one news mention by cancer type. *NH, non-Hodgkin. ** Some outliers are not displayed in the figure as the y-axis was truncated at Q3 + 1.5 *IQR.